Immunis, Inc. is a biotechnology company developing immune‑modulating, regenerative biologic therapies. Its research focuses on cell‑secreted protein compositions (the secretome)—including cytokines and growth factors—intended to rebalance immune signaling and support tissue maintenance in disorders associated with inflammation and age‑ or disease‑related decline.
The company advances off‑the‑shelf, protein‑based therapeutic candidates with potential application in degenerative and atrophic conditions. Activities span discovery, translational research, and process development aimed at scalable, well‑characterized manufacturing of biologic products.
Official website: immunisbiomedical.com
